University of Chicago Medicine

Comprehensive Cancer Center

Chicago, IL

Accepting patients

ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Pre-Transplant
  • Phase 2

Accepting patients

Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

Intensity Modulated Total Marrow Irradiation

A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Learn more
  • Allogeneic Stem Cell Transplant
  • Radiation
  • Phase 1

Accepting patients

Mismatched Related vs. Matched Unrelated Donor

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Monoclonal Antibody
  • Phase 3

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Learn more
  • Phase 1/2

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Learn more
  • Genetic Sequencing
  • Phase 2

Accepting patients

LP-118

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF
Learn more
  • BCL-2 Inhibitor
  • Bcl/xL Inhibitor
  • Phase 1

Not yet accepting

Impact of Non-Profit on Patient Outcomes & Care

The Impact of a Non-Profit Cancer Advocacy Organization on Patient Reported Outcomes and Access to Care: A Multisite, Longitudinal Trial
Learn more
  • Randomization
  • Observational Trial